Here's the plan. We'll trace where GLP-1 comes from, how a desert lizard ended up in a UK prescription, what happens in your stomach and brain, and the limits of what any injection can do without food doing its part too.
Ozempic. Wegovy. Mounjaro. Three names, one enormous cultural moment. Millions of prescriptions, a thousand headlines, and somewhere in the middle, a genuine question nobody quite answers on a chemist's leaflet: what is actually happening inside the body when appetite just switches down. Not willpower. Not a diet trick. A hormone, copied, extended, and injected. Tonight, we open the mechanism up. How it works, why hunger goes quiet, and what these drugs were never designed to do.
GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases naturally after you eat. It tells your pancreas to manage blood sugar, and it tells your brain you've had enough. The catch: your own GLP-1 breaks down within minutes. Blink, and it's gone. The entire drug class exists to solve that one problem — keep the hormone's message playing for hours, or even a week, instead of switching off almost immediately.
Here's the strange bit. In the 1990s, scientists studying the Gila monster, a venomous lizard from the American southwest, found a compound in its saliva called exendin-4. It mimicked GLP-1, but lasted far longer in the body. That discovery became exenatide, the first drug of this class, approved for type 2 diabetes in 2005. Everything since — semaglutide, tirzepatide — is a refined descendant of that original lizard-derived idea.
Before any of this was about weight, it was about type 2 diabetes. These drugs were designed to help the pancreas release insulin appropriately and keep blood sugar steadier through the day. Weight loss was a noticed side effect in early trials, consistent enough that manufacturers ran separate studies, at different doses, specifically for weight management. That's why Ozempic and Wegovy share an active ingredient, semaglutide, but are licensed for different purposes.
Turning a fragile hormone into a usable medicine took chemistry. Scientists altered the molecule's structure so the body's usual enzymes can't break it down quickly, and attached a fatty acid chain that lets it bind to a protein in blood, releasing slowly. The result: a hormone signal that once lasted minutes now lasts roughly a week, which is why these medicines are typically injected weekly rather than daily.
In the pancreas, GLP-1 receptor agonists prompt insulin release specifically when blood sugar is high, and they dial down glucagon, a hormone that would otherwise push blood sugar up further. This is why the effect is described as glucose-dependent — it responds to your actual blood sugar level, rather than forcing insulin out regardless. It's precise, targeted signalling, not a blunt instrument.
Second effect: gastric emptying slows down. Food sits in the stomach longer before moving into the small intestine. Practically, that means the sensation of fullness from a normal meal lasts longer than it would otherwise, and the next wave of hunger arrives later. It's also the mechanism behind a commonly reported side effect, nausea, particularly when a dose increases, because the stomach is working through food more slowly than usual.
Tirzepatide, sold as Mounjaro, goes a step further. It acts on two gut hormone receptors at once, GLP-1 and a second one called GIP. Trial data has shown larger average weight changes with this dual approach compared with GLP-1 alone, though individual response always varies enormously from person to person. The dual mechanism is newer science, but the underlying principle, mimicking gut hormones that regulate appetite, is the same family of idea.
For someone with type 2 diabetes, steadier blood sugar is the primary point, and it matters for long-term health in its own right, independent of weight. For someone without diabetes taking these medicines for weight management, blood sugar tends to run more evenly too, which is one reason energy levels and cravings for quick sugar hits often change alongside appetite. It's the same mechanism, working on two different outcomes.
The molecule also reaches the hypothalamus, a small region deep in the brain that regulates hunger, and the brainstem, which processes signals of fullness from the gut. This is the part that surprised early researchers, a hormone once thought to work only on digestion turns out to have a direct line to the brain's appetite control centre. That crossover is the real engine behind reduced hunger, not the stomach alone.
People often describe it the same way: the constant background thinking about food, what to eat next, what's in the fridge, simply goes quiet. Researchers call this reduction in intrusive food thoughts a drop in what's informally known as food noise. It isn't the drug removing hunger by force. It's dampening the mental volume around food, so decisions about eating feel less effortful than before.
Combine the slower stomach with the brain signal, and the practical result is satiety arriving earlier in a meal. Many people report finishing a normal-sized plate and simply not wanting more, or losing interest partway through. This is genuinely physiological, not a matter of trying harder. The portion that once felt normal can start to feel like plenty, because the fullness signal is arriving on time, rather than late.
Underneath both effects is the vagus nerve, a long nerve running between the gut and the brainstem, constantly reporting on stomach stretch and nutrient content. GLP-1 receptor agonists appear to amplify signals along this pathway, so the brain receives a stronger, clearer message that food has arrived and enough has been eaten. It's an old communication line, just turned up in volume by the medicine.
Eat consistently less over weeks and months, and the body draws on stored energy, mostly from adipose tissue, to make up the difference. That's the same basic principle behind any sustained calorie deficit, the drug doesn't melt fat directly, it creates the conditions, via appetite, for the body to use its own reserves. The mechanism is old physiology. What's new is how reliably the appetite side gets switched down.
Here's an important limit. Weight lost on these medicines isn't exclusively fat, some comes from lean muscle too, as it does with most methods of weight loss. Research consistently points to strength work and adequate protein intake as the way to protect muscle during the process. The injection manages appetite. It has no opinion on what you actually eat, or whether you move your body.
Nausea, constipation, and stomach discomfort are commonly reported, particularly early on or after a dose increases, tracing directly back to that slowed digestion. Everyone's experience differs, and how a person responds, tolerates, or should adjust anything at all is entirely a conversation for a GP or pharmacist, not a general explainer. What we can say plainly is that these effects are a known, documented part of how the mechanism behaves.
The appetite-quieting effect depends on the hormone signal staying present. Evidence suggests that when treatment stops, appetite and food noise tend to return over time, for many though not all people, which is why long-term plans and expectations are worth discussing directly with a GP. This isn't a comment for or against any individual's treatment. It's simply how the mechanism is understood to behave once the signal is withdrawn.
One thing worth saying plainly: nothing here decides what's on the fork. Appetite quieter or not, the meal still needs protein, fibre, and enough nutrients to function well on less food overall. That's the genuinely useful bit to focus on, regardless of what's happening with any prescription, because a smaller appetite fed badly is still a smaller appetite fed badly. The mechanism handles hunger. It never handles the shopping list.
Does it matter what I actually eat while I'm on it, or does the drug do the work?
The drug quiets appetite, it doesn't pick your food. Protein and fibre still matter, especially with less room on the plate. That's the food side SugarCoach can help with. (answer generated by SugarCoach, the AI coach)
General lifestyle education, not medical advice — personal medical decisions belong with your GP or pharmacist.